PROGRAM MANAGER: Nick Kacsandi, M.S.
OPPORTUNITY: Depending on the nature and scope of the proposed technical solution, this RFP could result in one or more of the following arrangements with the sponsoring client: technology licensing or acquisition, supplier agreement, contract research and development, joint development, proof of concept leading to commercial scale-up, technical consulting
Phase 1 - Initial discussions with top respondents under NDA (Q2 2015)
Phase 2 - Proof of concept within 6 months (Q3/Q4 2015)
Phase 3 - To be determined / Development and scale-up to commercialization (12-18 months) (by Q1 2017)
SOLUTION PROVIDER HELP DESK:
NineSigma, representing a Global Specialty Products Manufacturer, invites proposals for novel solutions to extend the life of menthol and similar active ingredients when applied to human skin. In particular, the client is seeking to achieve a pain relieving effect of at least 6 hours from the point of initial application.
Topical delivery mechanisms are routinely employed in the treatment a range of conditions and ailments, including infections, inflammation, and musculoskeletal pain. The crucial element to any topical application is the degree, rate and efficiency with which the active ingredients are able to penetrate the skin prior to evaporation or degradation. In the client’s field of products, traditional active ingredients such as menthol, lidocaine and salicylic acid are delivered via a variety of media applied to the skin to relieve pain and swelling. Variations in the loading concentration of these actives does not necessarily increase the duration of pain relief and irritation.
NineSigma’s client seeks to identify technologies that can measurably enhance the effects of their product beyond simply adjusting the amount of active ingredient in the end-product. Any technologies that could extend the pain relieving properties of active ingredients are of significant interest, including – but not limited to – technologies to enhance the transfer of actives through skin and/or technologies to increase the duration of exposure on skin. The client is open to funding or collaborating on work related to development or validation of regulatory claims / clinical trials.
Anticipated Project Phases or Project Plan
Phase 1 – Initial discussions under NDA
Phase 2 – Proof of technical concept
Phase 3 – Commercialization and optimization of technical solution, including:
The successful technology will:
Possible approaches might include, but are not limited to:
The following approaches are not of interest:
To respond, please make sure you are registered in NineSights, as it will prompt you to log in. Then, use the Response options at the top or bottom of the page. You may submit supplemental files in addition to your completed response form.
Appropriate responses will use the response template and address the following:
Team description and related experience